This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Sanofi Pasteur Brings Fluzone(R) Intradermal Vaccine Coop De Quill VacciNation Tour To Raleigh CVS/pharmacy To Raise Awareness About Importance Of Annual Flu Immunization And Vaccine Options For Adults

Stocks in this article: SNY

The survey also showed that 53 percent of adults 18 through 64 years of age who were vaccinated annually reported that their vaccination experience would be better if the needle was much smaller, and 65 percent said their experience would be better if access to the flu shot was more convenient.

A local survey of 403 adults in Raleigh revealed similar results as seven out of every ten (71 percent) adults 18 through 64 years of age said if they had influenza, they fear spreading the virus to their loved ones, yet over half (55 percent) of adults said they are not vaccinated annually.

Flu clinic attendees will have the opportunity to have one-on-one discussions with a CVS pharmacist and a MinuteClinic nurse practitioner to better understand the importance of annual influenza vaccination, how to help protect themselves and their loved ones, and the various vaccine options that are available for adults 18 through 64 years of age this flu season. Attendees can also get immunized with Fluzone Intradermal vaccine. Age and health-related restrictions may apply. 

The Coop de Quill vehicle, which features a supersized rooftop 3D structure of the Fluzone Intradermal vaccine, will be on-site for attendees to interact with. 

For adults unable to attend the flu clinic event on Thursday, immunization options, including Fluzone Intradermal vaccine, are available at all CVS/pharmacy and MinuteClinic locations in Raleigh throughout the season.   

Fluzone Intradermal vaccine is the only FDA-approved intradermal flu vaccine for adults 18 through 64 years of age in the United States. The device features an ultra-thin, 90 percent smaller needle that works just under the skin to help provide adults with the flu protection they need.

To find out where Fluzone Intradermal vaccine is available in your area, or to learn more about Fluzone Intradermal vaccine, visit www.Fluzone.com.

After the event in Raleigh, the Coop de Quill vehicle will be making its final stop of the tour this flu season in Baltimore.

About Fluzone Intradermal Vaccine Coop de Quill VacciNation Tour The Fluzone Intradermal Vaccine Coop de Quill VacciNation Tour is a national initiative that aims to raise awareness about the seriousness of influenza and the various vaccine options that are available for adults this flu season. Sanofi Pasteur and Actor Chris O'Donnell are teaming up to educate adults, a sometimes overlooked population, that the single most important thing they can do to help prevent getting or spreading the flu is to get their annual vaccination. Chris will share his personal flu vaccination experience and help to educate about this potentially deadly disease and vaccine options through various media activities this flu season. 

Additionally, the Coop de Quill VacciNation Tour is joining forces with various retailers, including Walgreens, CVS and Rite Aid, to bring Fluzone Intradermal vaccine to cities across the nation. The Coop de Quill vehicle will be making a stop in five tour cities: Baltimore, Chicago, Raleigh, San Francisco, and Seattle. At each stop attendees will have the opportunity to have one-on-one discussions with clinic pharmacists to better understand the importance of annual influenza vaccination and the various vaccine options available to them. Attendees can also get immunized with Fluzone Intradermal vaccine.

The Fluzone Intradermal Vaccine Coop de Quill VacciNation Tour is a program of Sanofi Pasteur, makers of Fluzone Intradermal vaccine.

About InfluenzaInfluenza is a serious respiratory illness that is easily spread and can lead to severe complications, even death. Each year in the U.S., 1 in 5 people, or up to 20 percent of the population gets the flu, and on average, influenza and its related complications result in approximately 226,000 hospitalizations. Influenza seasons are unpredictable and can be severe. Depending on virus severity during the influenza season, annual deaths can range from a low of 3,000 to a high of about 49,000 people. Combined with pneumonia, influenza is the nation's ninth leading cause of death. Vaccination is safe and effective and the best way to help prevent influenza and its complications.

About Fluzone Intradermal VaccineFluzone Intradermal vaccine, the only FDA-approved intradermal flu vaccine in the United States, is an inactivated influenza virus vaccine given to people 18 through 64 years of age for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

The Fluzone Intradermal vaccine needle is an ultra-thin microneedle that is 90 percent smaller and only goes as deep as the skin's surface to help protect against the flu.  Smaller than a grain of rice, the microneedle is only 1.5mm long, which is about the same as the thickness of a U.S. penny.

2 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,862.20 +34.45 0.19%
S&P 500 2,070.99 -1.84 -0.09%
NASDAQ 4,802.4870 +15.17 0.32%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs